{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:30:15Z","timestamp":1794965415315,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in <jats:italic>COL7A1<\/jats:italic>, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating <jats:italic>COL7A1<\/jats:italic> containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDEB mice and human RDEB xenografts. Subsequently, a randomized, placebo-controlled, phase 1 and 2 clinical trial (NCT03536143) evaluated matched wounds from nine RDEB patients receiving topical B-VEC or placebo repeatedly over 12\u2009weeks. No grade 2 or above B-VEC-related adverse events or vector shedding or tissue-bound skin immunoreactants were noted. HSV-1 and C7 antibodies sometimes presented at baseline or increased after B-VEC treatment without an apparent impact on safety or efficacy. Primary and secondary objectives of C7 expression, anchoring fibril assembly, wound surface area reduction, duration of wound closure, and time to wound closure following B-VEC treatment were met. A patient-reported pain\u2013severity secondary outcome was not assessed given the small proportion of wounds treated. A global assessment secondary endpoint was not pursued due to redundancy with regard to other endpoints. These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.<\/jats:p>","DOI":"10.1038\/s41591-022-01737-y","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T16:02:52Z","timestamp":1648483372000},"page":"780-788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9576-0456","authenticated-orcid":false,"given":"Irina","family":"Gurevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-0610","authenticated-orcid":false,"given":"PeiPei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Dolorito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Reitze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isin Sinem","family":"Bagci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunju","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visesha","family":"Kakarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Yenamandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5463-977X","authenticated-orcid":false,"given":"Mark","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-8041","authenticated-orcid":false,"given":"Sara F.","family":"Tufa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Keene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7650-0835","authenticated-orcid":false,"given":"Andrew P.","family":"South","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma M.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-8046","authenticated-orcid":false,"given":"M. Peter","family":"Marinkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"1737_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"J-D Fine","year":"2016","unstructured":"Fine, J.-D. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol. 152, 1231\u20131238 (2016).","journal-title":"JAMA Dermatol."},{"key":"1737_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1083\/jcb.138.3.719","volume":"138","author":"P Rousselle","year":"1997","unstructured":"Rousselle, P. et al. Laminin 5 binds the NC-1 domain of type VII collagen. J. Cell Biol. 138, 719\u2013728 (1997).","journal-title":"J. Cell Biol."},{"key":"1737_CR3","doi-asserted-by":"publisher","first-page":"14516","DOI":"10.1074\/jbc.272.23.14516","volume":"272","author":"M Chen","year":"1997","unstructured":"Chen, M. et al. Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal\u2013dermal adherence in human skin. J. Biol. Chem. 272, 14516\u201314522 (1997).","journal-title":"J. Biol. Chem."},{"key":"1737_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1083\/jcb.131.2.551","volume":"131","author":"L Bruckner-Tuderman","year":"1995","unstructured":"Bruckner-Tuderman, L. et al. Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain. J. Cell Biol. 131, 551\u2013559 (1995).","journal-title":"J. Cell Biol."},{"key":"1737_CR5","unstructured":"Marinkovich, M. P. Inherited epidermolysis bullosa. In Fitzpatrick\u2019s Dermatology 9th edn (eds Kang, S. et al.) Ch. 60 (McGraw Hill Medical, 2019)."},{"key":"1737_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has, C. et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br. J. Dermatol. 183, 614\u2013627 (2020).","journal-title":"Br. J. Dermatol."},{"key":"1737_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01811-7","volume":"16","author":"JY Tang","year":"2021","unstructured":"Tang, J. Y. et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J. Rare Dis. 16, 175 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1737_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jid.2018.11.036","volume":"139","author":"MP Marinkovich","year":"2019","unstructured":"Marinkovich, M. P. & Tang, J. Y. Gene therapy for epidermolysis bullosa. J. Invest. Dermatol. 139, 1221\u20131226 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"1737_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa0910501","volume":"363","author":"JE Wagner","year":"2010","unstructured":"Wagner, J. E. et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. J. Med. 363, 629\u2013639 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1737_CR10","doi-asserted-by":"publisher","first-page":"e130554","DOI":"10.1172\/jci.insight.130554","volume":"4","author":"S Eichstadt","year":"2019","unstructured":"Eichstadt, S. et al. Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight 4, e130554 (2019).","journal-title":"JCI Insight"},{"key":"1737_CR11","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jama.2016.15588","volume":"316","author":"Z Siprashvili","year":"2016","unstructured":"Siprashvili, Z. et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA 316, 1808\u20131817 (2016).","journal-title":"JAMA"},{"key":"1737_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","volume":"551","author":"T Hirsch","year":"2017","unstructured":"Hirsch, T. et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 551, 327\u2013332 (2017).","journal-title":"Nature"},{"key":"1737_CR13","doi-asserted-by":"publisher","first-page":"e126243","DOI":"10.1172\/jci.insight.126243","volume":"4","author":"SM Lwin","year":"2019","unstructured":"Lwin, S. M. et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight 4, e126243 (2019).","journal-title":"JCI Insight"},{"key":"1737_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/12856","volume":"17","author":"H Fan","year":"1999","unstructured":"Fan, H., Lin, Q., Morrissey, G. R. & Khavari, P. A. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat. Biotechnol. 17, 870\u2013872 (1999).","journal-title":"Nat. Biotechnol."},{"key":"1737_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley, J. L., de Jong, Y. P., Terhorst, C. & Herzog, R. W. Immune responses to viral gene therapy vectors. Mol. Ther. 28, 709\u2013722 (2020).","journal-title":"Mol. Ther."},{"key":"1737_CR16","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00018-008-7570-z","volume":"65","author":"EE Heldwein","year":"2008","unstructured":"Heldwein, E. E. & Krummenacher, C. Entry of herpesviruses into mammalian cells. Cell. Mol. Life Sci. 65, 1653\u20131668 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"1737_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fcimb.2019.00127","volume":"9","author":"EI Tognarelli","year":"2019","unstructured":"Tognarelli, E. I. et al. Herpes simplex virus evasion of early host antiviral responses. Front. Cell. Infect. Microbiol. 9, 127 (2019).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"1737_CR18","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3389\/fimmu.2019.02196","volume":"10","author":"L Yang","year":"2019","unstructured":"Yang, L. et al. Innate immune evasion of alphaherpesvirus tegument proteins. Front. Immunol. 10, 2196 (2019).","journal-title":"Front. Immunol."},{"key":"1737_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature16506","volume":"529","author":"ML Oldham","year":"2016","unstructured":"Oldham, M. L. et al. A mechanism of viral immune evasion revealed by cryo-EM analysis of the TAP transporter. Nature 529, 537\u2013540 (2016).","journal-title":"Nature"},{"key":"1737_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-4939-9814-2_4","volume":"2060","author":"WF Goins","year":"2020","unstructured":"Goins, W. F. et al. Engineering HSV-1 vectors for gene therapy. Methods Mol. Biol. 2060, 73\u201390 (2020).","journal-title":"Methods Mol. Biol."},{"key":"1737_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2174\/156652305774329285","volume":"5","author":"AL Epstein","year":"2005","unstructured":"Epstein, A. L., Marconi, P., Argnani, R. & Manservigi, R. HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr. Gene Ther. 5, 445\u2013458 (2005).","journal-title":"Curr. Gene Ther."},{"key":"1737_CR22","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/JCI34292","volume":"118","author":"A Fritsch","year":"2008","unstructured":"Fritsch, A. et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J. Clin. Invest. 118, 1669\u20131679 (2008).","journal-title":"J. Clin. Invest."},{"key":"1737_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1172\/JCI200317193","volume":"111","author":"S Ortiz-Urda","year":"2003","unstructured":"Ortiz-Urda, S. et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J. Clin. Invest. 111, 251\u2013255 (2003).","journal-title":"J. Clin. Invest."},{"key":"1737_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature11661","volume":"493","author":"M Kretz","year":"2013","unstructured":"Kretz, M. et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature 493, 231\u2013235 (2013).","journal-title":"Nature"},{"key":"1737_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1365-2133.2004.05933.x","volume":"150","author":"N Ishii","year":"2004","unstructured":"Ishii, N. et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br. J. Dermatol. 150, 843\u2013851 (2004).","journal-title":"Br. J. Dermatol."},{"key":"1737_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1285-x","volume":"17","author":"HH Ayoub","year":"2019","unstructured":"Ayoub, H. H., Chemaitelly, H. & Abu-Raddad, L. J. Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. BMC Med. 17, 57 (2019).","journal-title":"BMC Med."},{"key":"1737_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.jaad.2020.08.118","volume":"85","author":"DC Solis","year":"2021","unstructured":"Solis, D. C. et al. Classification of 2 distinct wound types in recessive dystrophic epidermolysis bullosa: a retrospective and cohort natural history study. J. Am. Acad. Dermatol. 85, 1296\u20131298 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1737_CR28","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1172\/JCI92707","volume":"127","author":"DT Woodley","year":"2017","unstructured":"Woodley, D. T. et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J. Clin. Invest. 127, 3028\u20133038 (2017).","journal-title":"J. Clin. Invest."},{"key":"1737_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1083\/jcb.104.3.611","volume":"104","author":"DR Keene","year":"1987","unstructured":"Keene, D. R., Sakai, L. Y., Lunstrum, G. P., Morris, N. P. & Burgeson, R. E. Type VII collagen forms an extended network of anchoring fibrils. J. Cell Biol. 104, 611\u2013621 (1987).","journal-title":"J. Cell Biol."},{"key":"1737_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","volume":"17","author":"MA Kotterman","year":"2015","unstructured":"Kotterman, M. A., Chalberg, T. W. & Schaffer, D. V. Viral vectors for gene therapy: translational and clinical outlook. Annu. Rev. Biomed. Eng. 17, 63\u201389 (2015).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"1737_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymgme.2008.12.016","volume":"96","author":"JM Wilson","year":"2009","unstructured":"Wilson, J. M. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol. Genet. Metab. 96, 151\u2013157 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"1737_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1566523211313030006","volume":"13","author":"S Knight","year":"2013","unstructured":"Knight, S., Collins, M. & Takeuchi, Y. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis. Curr. Gene Ther. 13, 211\u2013227 (2013).","journal-title":"Curr. Gene Ther."},{"key":"1737_CR33","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI79213","volume":"125","author":"RJ Chandler","year":"2015","unstructured":"Chandler, R. J. et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Invest. 125, 870\u2013880 (2015).","journal-title":"J. Clin. Invest."},{"key":"1737_CR34","doi-asserted-by":"crossref","unstructured":"Gene therapy needs a long-term approach. Nat. Med. 27, 563 (2021).","DOI":"10.1038\/s41591-021-01333-6"},{"issue":"455","key":"1737_CR35","doi-asserted-by":"publisher","first-page":"eaas9668","DOI":"10.1126\/scitranslmed.aas9668","volume":"10","author":"RJ Cho","year":"2018","unstructured":"Cho, R. J. et al. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci. Transl. Med. 10(455), eaas9668 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1737_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/mt.2008.234","volume":"17","author":"J Remington","year":"2009","unstructured":"Remington, J. et al. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol. Ther. 17, 26\u201333 (2009).","journal-title":"Mol. Ther."},{"key":"1737_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/aja.1001970404","volume":"197","author":"MP Marinkovich","year":"1993","unstructured":"Marinkovich, M. P., Keene, D. R., Rimberg, C. S. & Burgeson, R. E. Cellular origin of the dermal\u2013epidermal basement membrane. Dev. Dyn. 197, 255\u2013267 (1993).","journal-title":"Dev. Dyn."},{"key":"1737_CR38","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1177\/0963689719857657","volume":"28","author":"DM Supp","year":"2019","unstructured":"Supp, D. M. et al. Collagen VII expression is required in both keratinocytes and fibroblasts for anchoring fibril formation in bilayer engineered skin substitutes. Cell Transplant. 28, 1242\u20131256 (2019).","journal-title":"Cell Transplant."},{"key":"1737_CR39","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/bjd.13737","volume":"173","author":"ES Gorell","year":"2015","unstructured":"Gorell, E. S., Nguyen, N., Siprashvili, Z., Marinkovich, M. P. & Lane, A. T. Characterization of patients with dystrophic epidermolysis bullosa for collagen VII therapy. Br. J. Dermatol. 173, 821\u2013823 (2015).","journal-title":"Br. J. Dermatol."},{"key":"1737_CR40","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jaad.2020.03.028","volume":"85","author":"VA Eng","year":"2021","unstructured":"Eng, V. A. et al. Patient reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: a global cross-sectional survey. J. Am. Acad. Dermatol. 85, 1161\u20131167 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1737_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1749-6632.2009.04363.x","volume":"1170","author":"MI Koster","year":"2009","unstructured":"Koster, M. I. Making an epidermis. Ann. NY Acad. Sci. 1170, 7\u201310 (2009).","journal-title":"Ann. NY Acad. Sci."},{"key":"1737_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1083\/jcb.119.3.695","volume":"119","author":"MP Marinkovich","year":"1992","unstructured":"Marinkovich, M. P., Lunstrum, G. P., Keene, D. R. & Burgeson, R. E. The dermal\u2013epidermal junction of human skin contains a novel laminin variant. J. Cell Biol. 119, 695\u2013703 (1992).","journal-title":"J. Cell Biol."},{"key":"1737_CR43","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm1196-1263","volume":"2","author":"KA Choate","year":"1996","unstructured":"Choate, K. A., Medalie, D. A., Morgan, J. R. & Khavari, P. A. Corrective gene transfer in the human skin disorder lamellar ichthyosis. Nat. Genet. 2, 1263\u20131267 (1996).","journal-title":"Nat. Genet."},{"key":"1737_CR44","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1083\/jcb.103.4.1577","volume":"103","author":"LY Sakai","year":"1986","unstructured":"Sakai, L. Y., Keene, D. R., Morris, N. P. & Burgeson, R. E. Type VII collagen is a major structural component of anchoring fibrils. J. Cell Biol. 103, 1577\u20131586 (1986).","journal-title":"J. Cell Biol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01737-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T18:09:57Z","timestamp":1650478197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01737-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01737-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P.M. received funding from Krystal Biotech to conduct this study through a sponsored research award administered through the Stanford University Office of Research Management. M.P.M. is also an investigator for the following companies that are studying molecular corrective therapies for recessive dystrophic epidermolysis bullosa: Castle Creek Pharmaceuticals, Abeona Therapeutics, WINGS therapeutics and Phoenix Tissue Repair. A.P.S. owns stock in Krystal Biotech. P.A., P.P.Z. and S.O., as well as H.L., N.R., N.S., M.O. and S.M.K. are employees of Krystal Biotech. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}